nonacog beta pegol
nonacog beta pegol is a pharmaceutical drug with 9 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
0
Mid Stage
6
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
7 of 7 finished
0.0%
0 ended early
0
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B
Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B
Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.
A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN
Adverse Event Data Collection From External Registries on Nonacog Beta Pegol
Clinical Trials (9)
A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B
Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B
Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.
A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN
Adverse Event Data Collection From External Registries on Nonacog Beta Pegol
Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773
Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B
Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients
Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B
All 9 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 9